Latest News for: tev

Edit

GROQ-seq Datasets Across Transcription Factors (LacI, RamR, VanR), T7 RNA Polymerase and TEV Protease (NIST - National Institute of Standards and Technology)

Public Technologies 20 Apr 2026
) Published. April 19, 2026. Author(s) ... Abstract ... Citation. BioRxiv ... (2026), GROQ-seq Datasets Across Transcription Factors (LacI, RamR, VanR), T7 RNA Polymerase and TEV Protease, BioRxiv, [online], https.//www.biorxiv.org/ (Accessed April 20, 2026).
Edit

Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ...

Nasdaq Globe Newswire 25 Mar 2026
– TEV ‘325, which targets IL-13 and TSLP, is being studied for the treatment of TH2-driven inflammatory diseases such as asthma and atopic dermatitis ... .
Edit

What Geminga's 100 TeV cutoff may mean for cosmic-ray acceleration in the Milky Way

Phys Dot Org 05 Mar 2026
This observation extends to the highest energies, above 100 tera-electron volts (TeV), ...
Edit

Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Pharmiweb 20 Feb 2026
Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. TEV-'749 is ...
Edit

Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults (Medincell SA)

Public Technologies 20 Feb 2026
Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. TEV-'749 is ...
  • 1

Article Search

tools
×
×
×
×